Pancreatic neuroendocrine tumor staging

Pancreatic neuroendocrine tumor Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pancreatic neuroendocrine tumor from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Pancreatic neuroendocrine tumor staging On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pancreatic neuroendocrine tumor staging All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pancreatic neuroendocrine tumor staging
CDC on Pancreatic neuroendocrine tumor staging
Pancreatic neuroendocrine tumor staging in the news
Blogs on Pancreatic neuroendocrine tumor staging
Directions to Hospitals Treating Pancreatic neuroendocrine tumor
Risk calculators and risk factors for Pancreatic neuroendocrine tumor staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Staging

The 2010 WHO classification of tumors of the digestive system grades all the neuroendocrine tumors into three categories, based on their degree of cellular differentiation (from well-differentiated "NET G1" through to poorly-differentiated "NET G3"). The NCCN recommends use of the same AJCC-UICC staging system as pancreatic adenocarcinoma. Using this scheme, the stage by stage outcomes for PanNETs are dissimilar to pancreatic exocrine cancers. A different TNM system for PanNETs has been proposed by The European Neuroendocrine Tumor Society.